JJ竞技开盘平台JJ竞技 2022 ; 378 doi: https://doi.org/10.1136/bmj.o2192 (Published 08 September 2022) Cite this as: JJ竞技 2022;378:o2192
- Ingrid Torjesen
- The JJ竞技
The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine nasal spray for treatment resistant depression was unfair because its appraisal did not explain fully how the uncertainties in the evidence were taken into account in the decision making, an independent appeal panel has ruled. 1
NICE draft guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be made available on the NHS because of uncertainties over its clinical efficacy and cost effectiveness. 2 3 After two consultations, NICE maintained its view in the final appraisal document published in May this year. 4
In June esketamine’s manufacturer, Janssen, and the Royal College of Psychiatrists appealed the decision, arguing that NICE had acted unfairly and exceeded its powers in not recommending the treatment and that the decision was unreasonable in light of the evidence submitted. …
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all JJ竞技 articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 ( excludes VAT )
You can download a PDF version for your personal record.